Live
FierceBiotechSalspera plans $91M IPO to fund phase 3 studies of salmonella-based cancer therapyAgilentJim Cramer on Agilent Technologies: “I Don’t Think You Need It” - Yahoo FinanceEndpoints NewsRA Capital, Forbion and Canaan appear to back Harbour's CTLA-4 partner SolsticeBioPharma DiveWith $100M, Vima pursues an oral drug for movement disordersIlluminaCapital International Inc. CA Boosts Stake in Illumina - National TodayIlluminaCapital International Inc. CA Boosts Stock Holdings in Illumina, Inc. $ILMN - MarketBeatThermo FisherBank of Montreal Can Has $247.14 Million Position in Thermo Fisher Scientific Inc. $TMO - MarketBeatThermo FisherIs Thermo Fisher Scientific (TMO) Fairly Priced After Recent Share Price Weakness? - simplywall.steLifeReplacing the immune system of the brainEndpoints NewsStudy suggests long non-coding RNA has potential as new class of genetic medicineCellImmune-microbiome coordination defines interferon setpoints in healthy humansCellBringing the genetically minimal cell to life on a computer in 4D
FierceBiotech Mar 11, 2026

Salspera plans $91M IPO to fund phase 3 studies of salmonella-based cancer therapy

Salspera plans $91M IPO to fund phase 3 studies of salmonella-based cancer therapy

Original
Body unavailable. Use the original source.

Directory

59 All